News

The inability to coordinate care for these seniors leads to more health problems, and higher costs.

A health kiosk-decision support system may be a novel and important approach to improve provider prescription patterns.

The impact of the reemergence of untreatable infections on our healthcare costs could be prohibitive. Find out what's being done about it.

Among the most significant changes today is the transformation of patients to health consumers. Here's how plans and providers should adapt.

Program aims to prevent drug diversion

FDA has approved empagliflozin and metformin hydrochloride (Synjardy, Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company) tablets for the treatment of adults with type 2 diabetes.

FDA has expanded approval of eltrombopag (Promacta, Novartis) to treat low blood platelet count in pediatric patients with chronic immune thrombocytopenic purpura.

Fortune describes the 5 fastest-growing US pharmaceutical manufacturers.

The drop in the number of uninsured may seem like a good thing, but managed care executives need to be on guard in three areas.

4 things formulary managers can do to save lives and resources.

Historically, behavioral health data hasn’t been part of the clinical medical record, yet this information can help providers more accurately predict health behaviors.

Time to answer might seem like a small feature on a remote island of healthcare data systems, but it's a linchpin of software usability for daily patient encounters.

First injectable cholesterol drugs approved

Spending on healthcare can be good, but in the case of diabetes, more spending likely means worsening outcomes.

FDA’s approval of the first 3D-printed pill – Spritam to control epileptic seizures – will have a major impact on the medical and pharmaceutical community as a whole.

FDA’s long-awaited approval of Addyi (flibanserin) to treat hypoactive sexual desire disorder in premenopausal women, is significant for the prescribing community.

Jardiance is the first diabetes drug that has also been shown to lower strokes, heart attacks and cardiovascular deaths, according to a new study.

It’s time for organizations to expand the way they think about and employ PAs by looking at how the profession can impact areas where there are real needs.

Cindy Cooke, president of the American Association of Nurse Practitioners, shares 10 ways nurse practitioners reduce healthcare costs while improving quality.

FDA has approved sNDA for new formulation of fentanyl buccal soluble film (Onsolis, BioDelivery Sciences International) CII for the management of breakthrough pain in patients with cancer who are opioid tolerant.

While FDA is proposing that bevacizumab (Avastin) for macular degeneration be used within 5 days of re-packaging to avoid development of endophthalmitis in patients, that precaution may not be necessary, according to a new study.

Managing cardiovascular drug trend could prove challenging

Entresto is the first in a new class of drugs, valsartan combined with sacubitril, a pro-drug of a compound that is a receptor‐neprilysin inhibitor (ARNI). It is taken orally twice daily. It was approved for heart failure patients with reduced ejection fraction based on the PARADIGM-HF trial.

Methodist Healthcare Ministries of South Texas, Inc. is relying on data to identify the most effective ways to proactively engage patients, and leveraging technology to share information between facilities and programs.

Your input is needed! Managed Healthcare Executive is curious about your thoughts regarding the State of the Healthcare Industry. Take our survey and the feedback you provide will be invaluable in helping MHE. Complete the survey and you can be entered to win a $300 Visa gift card!

FDA recently granted special approval of pediatric use of OxyContin in patients aged 11 to 16 years, under specific conditions.

Here are five ways healthcare organizations of all types, including managed care organizations, can improve patient adherence to prescribed medication therapies.

A study of tocilizumab (Actemra) in the treatment of rheumatoid arthritis (RA) found that the number of serious adverse events (SAEs) found in postmarketing data were similar to other populations from clinical trials and epidemiology data.

A look at some of the technology tools healthcare systems are using to reduce readmissions.